厄洛替尼治疗EGFR野生型晚期非小细胞肺癌的疗效分析

Clinical study on treatment of erlotinib in advanced NSCLC patients with EGFR wild-type

目的:评价厄洛替尼治疗EGFR野生型NSCLC的疗效及安全性。方法:31名III/IV期或术后复发,不携带EGFR敏感突变(外显子18、19、21)的NSCLC患者服用厄洛替尼(150 mg/d)。结果:术后再发的,EGFR野生型的,III期或IV期患者服用厄洛替尼(150 mg/d),1例完全缓解,4例部分缓解,8例疾病稳定。缓解率为17.2%,疾病控制率为44.8%。皮疹是最常见的不良反应(80.6%)。有两名患者出现了间质性肺病。但所有这些不良反应均为可逆的,没有出现治疗相关死亡。中位无进展生存时间及中位生存时间分别为2.1个月与7.7个月。结论:厄洛替尼可能会成为化疗耐受的EGFR野生型NSCLC患者的一个替代方案。

Objective:To evaluate the efficacy and safety of treatment with erlotinib in advanced NSCLC patients with EGFR wild-type.Methods:The data of 31 postoperative recurrence patients with EGFR wild type and stage III or IV take erlotinib(150 mg/day).Results:After taking erlotinib(150 mg/day),there were 1 cases appear complete remission,4 cases appear partial remission,8 cases appear stable disease.Response rate was 17.2%,the DCR was44.8%.Skin rash was the most common adverse reactions(80.6%).There were 2 cases appeared interstitial lung disease.But all these adverse reactions were reversible,there was no treatment-related death.The median progression-free survival time and the median survival time was 2.1 months and 7.7 months,respectively.Conclusion:Erlotinib may become an alternative solution with chemotherapy resistance in NSCLC patients with EGFR wild-type.